IL-17 Antibody Treatment Reduces Heart Inflammation in Viral Myocarditis
Author Information
Author(s): Fan Yang, Weifeng Wu, Yuluan Yan, Qing Kong, Yu Pang, Yanlan Huang
Primary Institution: Guangxi Cardiovascular Institute
Hypothesis
Does neutralizing IL-17 after the onset of viral myocarditis improve heart inflammation and survival rates in mice?
Conclusion
Neutralizing IL-17 with a monoclonal antibody after the onset of viral myocarditis reduces inflammation and improves survival rates in mice.
Supporting Evidence
- The survival rate of IL-17mAb group mice was significantly improved compared to the isotype control and PBS groups.
- IL-17mAb treatment reduced the severity of myocarditis as indicated by lower heart weight/body weight ratios and pathological scores.
- IL-17mAb decreased circulating levels of IL-17 compared to control groups.
Takeaway
This study shows that giving a special medicine to block a protein called IL-17 can help mice with heart problems caused by a virus feel better and live longer.
Methodology
Mice with viral myocarditis were treated with an IL-17 monoclonal antibody, and their survival rates and heart pathology were assessed.
Limitations
The study did not completely reduce VMC symptoms, and the effects of the IL-17 antibody may vary based on dosage and timing.
Participant Demographics
Specific pathogen-free male BALB/c mice, 6 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website